Loading company…
Riskpilot
← Back to search
Sign in
Get full access
AngElle Bioengineering ApS
APS
Active
CVR 43155881
N. Jespersens Vej 15
Engineering activities and related technical consultancy · NACE 7112
Est. 2022
— employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 45K
+2667% vs 2023
EBITDA margin
86.0%
+935% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK 38K
+935% vs 2023
EBITDA — year on year
DKK millions
0M
-0M
-1M
-1M
-1M
0M
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
DKK 45K
+2667%
EBITDA
DKK 38K
+935%
Net profit
DKK 38K
+935%
Total assets
DKK 141K
+44%
Equity
DKK 141K
+44%
Employees
—
—
Company information
Legal name
AngElle Bioengineering ApS
CVR number
43155881
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
20. marts 2022
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Contact
Address
N. Jespersens Vej 15
Phone
+4530613889
Email
AngElleBioEng@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Engineering activities and related technical consultancy
Companies in Frederiksberg
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
Income statement
DKK thousands
Item
2022
2023
2024
Revenue
67
2
45
Staff expenses
-0
-0
-0
EBITDA
62
-5
38
Depreciation & amort.
-0
-0
-0
EBIT
62
-5
38
Net financials
0
0
0
Profit before tax
62
-5
38
Tax
-0
-0
-0
Net profit
62
-5
38
Balance sheet
DKK thousands
Item
2022
2023
2024
Total assets
102
98
141
Equity
102
98
141
Long-term debt
0
0
0
Short-term debt
0
0
0
Total debt
0
0
0
Financial ratios
5-year trend
EBITDA margin
86.0%
This company
15.8%
Market median
+444% vs market
2022
2024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
2022
2024
Return on equity
27.2%
This company
18.4%
Market median
+48% vs market
2022
2024
Net profit margin
86.0%
This company
8.1%
Market median
+962% vs market
2022
2024
Asset turnover
0.32×
This company
1.12×
Market median
-71% vs market
2022
2024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-03-25 – 2022-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Irini Angelidaki
Individual
100%
100%
2022
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of AngElle Bioengineering ApS also hold positions in
0
other companies.
Person
Role here
Other companies